Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Silo Pharma, Inc. - Common Stock (NQ:SILO)

1.910 -0.160 (-7.73%)
Streaming Delayed Price Updated: 12:51 PM EDT, Sep 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
News headline image
Silo Pharma's New Ketamine Implant For Fibromyalgia And Chronic Pain Is In The Making ↗
Developmental-stage psychedelics biotech Silo Pharma (NASDAQ: SILO) has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant with... 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Entry into Ketamine Implant Therapeutic Research Project
Via Investor Brand Network
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Silo Pharma Signs Agreement to Develop First-in-Class Ketamine Implant Therapeutic
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Participate, Share Profile on Webull Platform
Via Investor Brand Network
News headline image
Silo Pharma Announces Participation on Webull Corporate Communications Service Platform
From Silo Pharma, Inc.
Via GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Agreement to Further Study Novel Joint Homing Peptide
Via Investor Brand Network
News headline image
Silo Pharma Commences Study of Novel Joint Homing Peptide SPU-21
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More ↗
Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... 
Via Benzinga
News headline image
Stress-Related Mood Disorders And Alzheimer's: Can This Patented Ketamine Drug Help? ↗
Silo Pharma Inc. (NASDAQ: SILO), one of the biotech companies developing next-generation psychedelic therapeutics, obtained a new US patent covering IP for its drug candidate SPC-15’s research and... 
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
Via Investor Brand Network
Topics Intellectual Property
Global Alzheimer’s Disease Diagnostics & Therapeutics Market Expected to Reach $9.6 Billion by 2027
Palm Beach, FL – May 9, 2023 – FinancialNewsMedia.com News Commentary – Alzheimer’s disease (AD) is a progressive and neurodegenerative disorder that attacks the brain’s nerve cells or neurons, which... 
Via FinancialNewsMedia
Topics Intellectual Property
Silo Pharma’s SPC-15 Awarded U.S. Patent to Protect Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
ENGLEWOOD CLIFFS, NJ – May 9, 2023 – Silo Pharma, Inc. (NASDAQ: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic... 
Via FinancialNewsMedia
Topics Intellectual Property
News headline image
Silo Pharma’s SPC-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More ↗
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a... 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Participation at Upcoming Psychedelic Drug Development Conference
Via Investor Brand Network
News headline image
Silo Pharma to Present at Psychedelic Drug Development Conference
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Stress, Anxiety, PTSD: 2 NASDAQ-Listed Drug Developers Advance Psychedelic-Inspired Meds ↗
Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD. 
Via Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Begins Development of Treatment for Anxiety-Related Disorders
Via Investor Brand Network
Topics Intellectual Property
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
ENGLEWOOD CLIFFS, NJ – April 19, 2023 – Silo Pharma, Inc. (NASDAQ:SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic... 
Via FinancialNewsMedia
News headline image
Silo Pharma Commences Formulation for SPC-15 Targeting Anxiety and PTSD Stress-Related Disorders
Data to Support Alzheimer’s Study 
From Silo Pharma, Inc.
Via GlobeNewswire
News headline image
Psyched: Canada's Case For Psilocybin Access And Microdose Trial, US Reform Update, Battle With DEA & More ↗
Canadian Patients Demand Access To Psilocybin: Federal Lawsuit, Official Petition & Failing Mechanism A patient-led lawsuit against the Canadian government is claiming access to therapeutic psilocybin... 
Via Benzinga
Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia
Via Investor Brand Network
News headline image
Silo Pharma To Patent Novel Ketamine-Based Treatment For Chronic Condition ↗
Biopharma company Silo Pharma Inc. 
Via Benzinga
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia
Via Investor Brand Network
Topics Intellectual Property
News headline image
Silo Pharma Announces filing of Patent for Treatment of Fibromyalgia
From Silo Pharma, Inc.
Via GlobeNewswire
PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Positioned as Frontrunner in Psychedelic Drugs Market
Via Investor Brand Network
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  On Tuesday, 74 companies achieved new lows for the year. 
Via Benzinga
News headline image
Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More ↗
Psychedelics Reform Update: 22 States Where Proposals Are Being Discussed & Local Moves Considered 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.